Business Wire

IFF Announces Voluntary Delisting from the Tel Aviv Stock Exchange in January 2021

Share

Regulatory News:

International Flavors & Fragrances Inc. (“IFF”) (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today announced that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (“TASE”).

Under applicable Israeli law, the delisting of IFF’s shares of common stock from trading on the TASE is expected to become effective in three months, on January 20, 2021. During this time, IFF’s shares will continue to be traded on the TASE. Following the delisting of IFF’s shares of common stock on the TASE, IFF’s shares will continue to be listed on the New York Stock Exchange (“NYSE”) and all IFF shares now traded on the TASE are expected to be transferred to the NYSE where they can continue to be traded.

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael DeVeau
Head of Investor Relations and Communications
212.708.7164
Michael.DeVeau@iff.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 15:00:00 EET | Press release

Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68

BitGo Holdings Announces Launch of Initial Public Offering12.1.2026 15:00:00 EET | Press release

BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, today announced the launch of its initial public offering of 11,821,595 shares of Class A common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the "SEC"). The offering consists of 11,000,000 shares of Class A common stock being offered by BitGo and 821,595 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo intends to grant the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of Class A common stock. The initial public offering price is expected to be between $15 and $17 per share. BitGo has applied to list its Class A common stock on the New York Stock Exchange under the ticker symbol "BTGO". Goldman Sachs & Co. LLC is acti

Esri’s Custom Chart Builder Adopted by the Shom (French Hydrographic and Oceanographic Office) for Nautical Chart Production12.1.2026 15:00:00 EET | Press release

Esri, the global leader in location intelligence, announced today that the Shom (French Hydrographic and Oceanographic Office) has officially adopted Custom Chart Builder (CCB) for automated production of all paper nautical charts. Following extensive testing and configuration, Shom confirmed that CCB-generated charts meet the stringent safety standards required by the French Navy, marking a pivotal advancement in automating maritime cartography and reinforcing its role as a pioneer in maritime digital transformation. “This adoption demonstrates that high-quality, regulation-compliant paper charts can now be produced without manual intervention, dramatically reducing production time and cost,” said Rafael Ponce, Esri principal maritime consultant. “Shom’s endorsement validates Esri’s CCB as a trusted solution for hydrographic offices worldwide, supporting the transition to digital-first workflows and e-navigation.” Over the course of 2024, Shom evaluated multiple software solutions and

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 14:30:00 EET | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate use, and to enhance monitoring and treatment procedures in participating hospitals. BOT+BAL is a chemotherapy- and radiation-f

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 14:30:00 EET | Press release

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production standard across Cellares’ global facilities. The leased premises comprise approximately 9,741 square meters (about 105,000 square feet LFA) of laboratory and office space within the Nexus building in Leiden, a newly construct

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye